Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > COMMENTARY
COMMENTARY
- New Prescription Form Shaking Things Up at Pharmacies
April 24, 2006
- Proposed Increases in Frequency of NHI Price Revisions
April 17, 2006
- JMA Needs to Establish New Partnership with LDP
April 17, 2006
- COMMENTARY 4 articles
April 3, 2006
- Tougher Pricing Policy, New Products Essential to Offset Impact of NHI Price Revision
March 27, 2006
- No Domestic Company Moves Despite Expected Growth: Vaccine Business
March 27, 2006
- FY2006 NHI Price Revision: Industry Succeeds in Defensive Efforts
March 13, 2006
- Effects of Medical Fee Revision Need to be Verified
March 6, 2006
- Pfizer Management, Labor See Signs of Snowbreak
March 6, 2006
- ＜COMMENTARY＞ New Dispensing Fees Nearly Decided
February 20, 2006
- Japan's Most Admired Pharma Companies P. Reed Maurer
February 20, 2006
- Frustrating Outcome for Industry: Exceptional NHI Price Reduction for Long-listed Drugs
February 13, 2006
- Requirements for External IRBs to Be Relaxed
February 13, 2006
- Astellas' Inventorship Issue with Professor Ochiai - What If This Were a US Case?
February 6, 2006
- COMMENTARY 2 articles
January 30, 2006
- JPLA SEMINAR
January 30, 2006
- Maurer's Healthcare Insight (72)
January 30, 2006
- Astellas' Inventorship Issue with Professor Ochiai - What If This Were a US Case?
January 30, 2006
- Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (II) -2-
January 30, 2006
- Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (II) -1-
January 30, 2006
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…